NASDAQ:CNSP CNS Pharmaceuticals (CNSP) Stock Price, News & Analysis $0.81 +0.00 (+0.46%) Closing price 04:00 PM EasternExtended Trading$0.83 +0.02 (+2.22%) As of 06:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About CNS Pharmaceuticals Stock (NASDAQ:CNSP) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get CNS Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.81▼$0.8450-Day Range$0.81▼$1.3652-Week Range$0.77▼$200.00Volume240,281 shsAverage Volume694,163 shsMarket Capitalization$4.43 millionP/E RatioN/ADividend YieldN/APrice Target$25.00Consensus RatingModerate Buy Company OverviewCNS Pharmaceuticals, Inc., a clinical pharmaceutical company, engages in the development of anti-cancer drug candidates for the treatment of brain and central nervous system tumors. The company's lead drug candidate is Berubicin, which completed Phase I clinical trial that is used for the treatment of glioblastoma multiforme. It has license agreements with Houston Pharmaceuticals, Inc., Reata Pharmaceuticals, Inc., Pomeranian Medical University, and The University of Texas M.D. Anderson Cancer Center; and a development agreement with WPD Pharmaceuticals Inc. The company was incorporated in 2017 and is based in Houston, Texas.Read More… CNS Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreCNSP MarketRank™: CNS Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.3 / 5Analyst RatingModerate Buy Consensus RatingCNS Pharmaceuticals has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Amount of Analyst CoverageCNS Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about CNS Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of CNS Pharmaceuticals is -0.01, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about CNS Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.36% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 75.13%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCNS Pharmaceuticals does not currently pay a dividend.Dividend GrowthCNS Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.36% of the float of CNS Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverCNS Pharmaceuticals has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in CNS Pharmaceuticals has recently decreased by 75.13%, indicating that investor sentiment is improving significantly. News and Social Media2.9 / 5News Sentiment1.29 News SentimentCNS Pharmaceuticals has a news sentiment score of 1.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.90 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for CNS Pharmaceuticals this week, compared to 1 article on an average week. Company Ownership0.0 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, CNS Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.07% of the stock of CNS Pharmaceuticals is held by insiders.Percentage Held by InstitutionsOnly 14.02% of the stock of CNS Pharmaceuticals is held by institutions.Read more about CNS Pharmaceuticals' insider trading history. Receive CNSP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for CNS Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address CNSP Stock News HeadlinesShort Interest in CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) Decreases By 75.1%June 12, 2025 | americanbankingnews.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Corporate UpdateMay 16, 2025 | finanznachrichten.deTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.June 16, 2025 | Porter & Company (Ad)CNS Pharmaceuticals Acquires Orphan Drug Designation For TPI 287 And Prices $5M Public OfferingMay 16, 2025 | nasdaq.comCNS Pharmaceuticals (NASDAQ: CNSP) Prices $5 Million Public Offering with Institutional InvestorMay 15, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Acquires Orphan Drug Designation for Novel, Late Stage Abeotaxane, TPI 287May 13, 2025 | finanznachrichten.deCNS Pharmaceuticals (NASDAQ: CNSP) Secures Orphan Drug Designation Transfer for TPI 287 in Brain Cancer IndicationsMay 13, 2025 | theglobeandmail.comCNS Pharmaceuticals, Inc.: CNS Pharmaceuticals Announces Pricing of $5 Million Public Offering Priced At-The-Market Under Nasdaq RulesMay 13, 2025 | finanznachrichten.deSee More Headlines CNSP Stock Analysis - Frequently Asked Questions How have CNSP shares performed this year? CNS Pharmaceuticals' stock was trading at $6.02 at the beginning of the year. Since then, CNSP shares have decreased by 86.5% and is now trading at $0.8130. View the best growth stocks for 2025 here. How were CNS Pharmaceuticals' earnings last quarter? CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) released its quarterly earnings results on Thursday, May, 15th. The company reported ($1.58) EPS for the quarter. When did CNS Pharmaceuticals' stock split? Shares of CNS Pharmaceuticals reverse split on Friday, February 21st 2025. The 1-50 reverse split was announced on Wednesday, February 19th 2025. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 20th 2025. An investor that had 100 shares of stock prior to the reverse split would have 2 shares after the split. When did CNS Pharmaceuticals IPO? CNS Pharmaceuticals (CNSP) raised $9 million in an IPO on Friday, November 8th 2019. The company issued 2,100,000 shares at $4.00-$5.00 per share. Benchmark acted as the underwriter for the IPO. How do I buy shares of CNS Pharmaceuticals? Shares of CNSP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of CNS Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that CNS Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), CymaBay Therapeutics (CBAY), Advanced Micro Devices (AMD), Broadcom (AVGO) and GE Aerospace (GE). Company Calendar Last Earnings5/15/2025Today6/16/2025Next Earnings (Estimated)8/13/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CNSP CIK1729427 Webwww.cnspharma.com Phone800-946-9185FaxN/AEmployees5Year FoundedN/APrice Target and Rating Average Stock Price Target$25.00 High Stock Price Target$25.00 Low Stock Price Target$25.00 Potential Upside/Downside+2,894.0%Consensus RatingModerate Buy Rating Score (0-4)2.50 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($3,748.50) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$18.85 million Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on Assets-515.32% Debt Debt-to-Equity RatioN/A Current Ratio1.82 Quick Ratio1.82 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($35.66) per share Price / Book-0.02Miscellaneous Outstanding Shares5,462,000Free Float57,447,000Market Cap$4.56 million OptionableNot Optionable Beta2.65 7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free Report This page (NASDAQ:CNSP) was last updated on 6/16/2025 by MarketBeat.com Staff From Our PartnersAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredSomething Big Is Coming...Man who predicted Lehman Crash Warns "Get OUT of Cash" He predicted the 2008 crisis and recommended shortin...Stansberry Research | SponsoredBREAKING: Trump vs. Elon Feud Threatens Your Retirement – Protect Yourself NOW"This isn't just a war of words. This is a financial time bomb. The escalating battle between Donald Trump a...American Alternative | SponsoredThe mainstream media is wrong about AI — againThe mainstream media got it wrong … yet again. Chinese AI chatbot DeepSeek turned the tech world on its hea...Weiss Ratings | SponsoredSocial Security Boss drops huge Elon announcement…Elon's Successor? Elon Musk and President Trump's new feud is all over the news... but before he left Washi...Altimetry | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CNS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share CNS Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.